Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-04-08
1999-11-02
Kunz, Gary L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514588, 514441, A61K 3170, A61K 3117
Patent
active
059770864
ABSTRACT:
A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a combination of compounds selected from the group consisting of hydroxyurea, a nucleoside analog, and a protease inhibitor.
REFERENCES:
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5110600 (1992-05-01), Green
patent: 5250563 (1993-10-01), Chen et al.
patent: 5300059 (1994-04-01), Rubinstein et al.
Fundamental Virology, Second Ed., Ch. 27 edited by Fields, et al. Raven Press Ltd., NY, NY 1991.
Borrow et al.; Nature Medicine, 3:(2) 205-211, 1997.
Goulder et al.; Nature Medicine, 3:(2) 212-217,,1997.
Mellors et al.; 272(5265) 1167-1170, May 1996.
Antiviral Therapy for Human Immunodefiency Virus Infections, E. De Clercq, Clinicial Microbiology Reviews 8:2, American Society for Microbiology (Apr. 1995).
Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication, F. Lori et al; Science 266: 801-805 (1994).
Hydroxyurea and AIDS: An Old Drug Finds a New Application? F. Lori et al. Aids Research and Human Retroviruses vol. 11, No. 10 Mary Ann Liebert, Inc. (1995).
Gao et al., Journal of Biological Chemistry, Apr. 29, 1994, 269(17); 12633-8. Divergent Anti-human Immunodefiency Virust Activity and Anabolic Phosphorylation . . . .
Gao et al., Journal of Clinical Investigation, May 10, 1993; 91(5):2326-33, Differential Phosphorylation of Azidothymidine, Dideoxycyctidine, and Dideoxyinosine in Resting and Activated Pheripheral Blood.
Zhu et al.; Science, vol. 261 (5125); 1179-81; Genotypic and Phenotypic Characterization of HIV-1 in Patients with Primary Infection, 1993.
van't Wout et al.; Journal of Clinical Investigation, Nov. 1994: 94(5): 2060-7. Macrophage-tropic Variants Initiate Human Immunodefiency Virus Type 1 Infection after Sexual, Parenteral, and Vertical Transmission.
Reinhardt et al.; Journal of Clinical Microbiology, Feb. 1995; 33(2), 292-7, Human Cord Blood Mononuclear Cells are Preferentially Infected by Non-Syncytium-Inducing, Macrophage-Tropic . . . .
Ometto et al.; AIDS, 1995 May 9(5); 427-34: Viral photype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission.
Cameron et al.; Journal of Experimental Medicine, Apr. 1, 1996; 183(4); 1851-6: The Interaction of Macrophage and Non-Macrophage Tropic Isolates of HIV-1 with Thymic and Tonsillar Dendritic.
Seminars in Oncology; R. C. Donehower, 19:3 (Suppl. 9), 11-19 (1992); Current Advances in Hydroxyurea Ther.
Zack et al.; Cell 61:213 (1990) HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure.
Zack et al.; Journal of Virology; 66:1717 (1992); Incompletely Reverse-Transcribed Human Immunodefiency Virus Type 1 Genomes in Quiescent Cells can Function as Intermediates . . . .
Stevenson et al.; EMBO J. 9:1551 (1990); HIV-1 Replication is controlled at the level of T Cell Activation and Proviral Integration.
Burinsky et al.; Science 254:423 (1991); Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection.
Lori et al.; Journal of Virology, 66:5067 (1992); Viral DNA Carried by Human Immunodeficiency Virus Type 1 Virions.
Pantaleo et al; Nature, 362(6418): 355-358 (1993); HIV Infection is Active and Progressive in Lymphoid Tissue During the Clinically Latent Stage of Disease.
Fox et al.; In Situ Hybridization for Detection of HIV RNA in Cells and Tissues; Current Protocols in Immunology, vol. 3 (Coligan et al. eds.) Wiley, NY, 1993.
Fox et al.; Microscopy Research and Technique; 25:78-84, 1993; In Situ Hybridization in HIV Research.
Methods in Molecular Biology, vol. 15: PCR Protocols; Humana Press, Inc. (1993).
Xiping et al.; Nature 1995; 373:117-122; Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection.
Saag et al.; The New England Journal of Medicine; 1993; 329:1065-72; A short-Term Clinical Evaluation of . . . .
Boom et al.; Journal of Clinical Microbiology; 28:495-503 (1990); A Rapid and Simple Method for Purification of Nucleic Acids.
van Gemen et al.; Journal of Virological Methods; 43:177-188(1993); Quantitation of HIV-1 RNA in Plasma.
Kievits et al.; Journal of Virological Methods 35:3 273-286(1991); NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection.
van Gemen et al.; Journal of Virological Methods; (1994) 49: 157-168; A One-Tube Quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labeled probes.
Katzenstein et al.; The New England Journal of Medicine; Oct. 1996. 10:335(15): 1091-8; The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in . . . .
Lisziewicz Julianna
Lori Franco
Kunz Gary L.
Looper Valerie E.
R.I.G.H.T.
LandOfFree
Method of inhibiting human immunodeficiency virus by combined us does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting human immunodeficiency virus by combined us, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting human immunodeficiency virus by combined us will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2135584